Clindamycin Phosphate In Dextrose 5% In Plastic Container

ANDA 65027, held by Abbott Labs. Clindamycin Phosphate.

As of Nov 15, 2026, ANDA 65027 (Clindamycin Phosphate In Dextrose 5% In Plastic Container), held by Abbott Labs, was first approved by FDA on Jun 29, 2001, with 2 approved supplements and 0 published complete response letters.

First approved: Jun 29, 2001
Supplements approved: 2
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below

Date	Submission	Status	Documents
Jun 29, 2001	Original application	Approved	Review

Products

3 strengths and forms


Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 6MG BASE/ML · injectable;injection	Clindamycin Phosphate	Discontinued
Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 12MG BASE/ML · injectable;injection	Clindamycin Phosphate	Discontinued
Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 18MG BASE/ML · injectable;injection	Clindamycin Phosphate	Discontinued

All 3 submissions, including labeling and manufacturing supplements


Sep 13, 2002	Supplement 1Manufacturing	Approved	None posted
Sep 13, 2002	Supplement 2Manufacturing	Approved	None posted
Jun 29, 2001	Original application	Approved	Review

Identifiers

Application: ANDA 65027
Drugs@FDA: Overview at FDA
Company: Abbott Laboratories

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters